1187 studies on GLP-1 agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This study provides compelling preliminary evidence that semaglutide, a well-known GLP-1 receptor agonist, could be a highly effective and novel treatment for intractable diarrhea, offering a new therapeutic option fo…
The findings from this review are highly significant, suggesting that modern antidiabetic drugs offer more than just blood sugar control. They may directly improve outcomes for patients with Peripheral Arterial Occlus…
This comprehensive review is vital for enhancing awareness among clinicians and patients regarding the potential ocular risks associated with GLP-1 RA treatment. It provides a crucial framework for identifying vulnera…
This study highlights the critical importance of long-term management strategies for obesity and overweight, even after successful initial weight loss with potent agents like tirzepatide. The significant weight regain…
This finding suggests that initiating Tirzepatide in patients with type 2 diabetes who are new to GLP-1 receptor agonists may offer a distinct and superior advantage in improving liver health, specifically regarding f…
This mathematical modeling study provides crucial insights into the long-term physiological adaptations that lead to the weight loss plateau observed with GLP-1 receptor agonists. Understanding these energy balance dy…
This review represents a conceptual shift in T2D management, proposing that cognitive preservation should become an explicit therapeutic objective, integrated with metabolic control. The identification of existing glu…
This research introduces a groundbreaking approach to treating obesity and diabetes by simultaneously targeting multiple metabolic pathways. By combining GLP-1R, GIPR, and PPARα/γ/δ agonism, this strategy could offer …
These findings are highly significant as they indicate that Lotiglipron has a low propensity for drug-drug interactions with a broad range of commonly used medications. This favorable DDI profile simplifies its potent…
This comprehensive review is critically important as it establishes a robust scientific rationale for further investigating GLP-1 RAs as a novel and potentially transformative therapeutic strategy for psoriasis, espec…
These findings are highly significant, suggesting a novel therapeutic avenue for addressing anhedonia and motivational deficits in Major Depressive Disorder, symptoms that are notoriously difficult to treat with exist…
This study reveals a notable disparity in the utilization of GLP1RAs among individuals with multiple sclerosis who possess cardiometabolic comorbidities that would warrant such treatment. The findings underscore the i…
This study highlights tirzepatide's profound potential as an effective add-on therapy for Type 2 Diabetes patients whose blood sugar remains poorly controlled despite existing insulin and metformin regimens. The dual …
The findings from this study, once published, could significantly advance our understanding of GLP-1 agonists beyond weight loss, specifically in treating binge eating disorder. If Liraglutide proves effective, it cou…
Establishing bioequivalence between different drug formulations is crucial for drug development. It ensures that any changes in formulation (e.g., for improved stability, manufacturing, or patient convenience) do not …
This Phase III comparative trial is significant because it directly compares three different GLP-1 RA formulations, potentially providing crucial data to guide treatment selection for obese patients. The findings coul…
PCOS is a complex condition with significant unmet needs, particularly for obese and infertile women who struggle with its multifaceted symptoms. If liraglutide demonstrates superior or even comparable efficacy to met…
If successful, this line of research could reposition GLP-1 agonists as potential neuroprotective agents, expanding their therapeutic utility beyond metabolic disorders. The findings, had they been positive, could hav…
This study provides strong evidence that Liraglutide 3.0mg is an effective and generally well-tolerated treatment option for managing weight regain after Roux-en-Y gastric bypass surgery. This is a crucial finding, as…
Understanding how different antidiabetic medications affect liver enzymes like ALT is crucial for managing patients with Type 2 Diabetes Mellitus (T2DM), especially given the high prevalence of co-occurring non-alcoho…
This foundational Phase 1 study was critical in establishing the initial safety and pharmacokinetic profile of liraglutide, a drug that later became a cornerstone in the treatment of Type 2 Diabetes and obesity. The p…
This study reinforces the efficacy of liraglutide as an add-on therapy for Type 2 Diabetes, particularly within a Japanese population. The findings suggest that combining liraglutide with insulin can lead to better gl…
The development of CagriSema is significant because it combines two potent mechanisms: Cagrilintide (an amylin analog) and Semaglutide (a GLP-1 receptor agonist), potentially offering synergistic effects for greater w…
If successful, this study could usher in a new era of precision medicine for obesity, moving beyond a 'one-size-fits-all' approach. The ability to use a simple saliva test to predict semaglutide efficacy could signifi…
Understanding patient experience, especially regarding injection site pain, is crucial for improving adherence to long-term treatments for conditions like Type 2 Diabetes and obesity. If one GLP-1 agonist consistently…
The insights gleaned from this large-scale, multi-country observational study will be invaluable for understanding the real-world effectiveness and safety profile of semaglutide for weight management. This data will h…
This study is critically important because obesity significantly impacts the health and longevity of kidney transplant recipients, increasing risks of complications and graft loss. If successful, this combined approac…
If successful, this Phase 3 trial could represent a paradigm shift in post-stroke care, offering a novel therapeutic strategy to enhance recovery beyond clot removal. Given the high global burden of stroke-related dis…
This Phase 4 pragmatic trial is crucial because it provides real-world evidence on semaglutide's long-term performance against a broad spectrum of existing Type 2 Diabetes treatments. Such data helps clinicians and pa…
This study is highly significant because it could establish Tirzepatide as more than just a powerful glucose-lowering agent, potentially offering a crucial benefit in addressing diabetes-related cognitive impairment. …
The successful completion of this Phase 1 safety and tolerability study is a pivotal step for LY3841136 and its potential role in obesity treatment. If LY3841136 proves to be safe and effective in combination with tir…
The findings from this study, once published, will be crucial for understanding the full therapeutic potential of incretin-based therapies beyond current GLP-1 receptor agonists. If the combined GIP and GLP-1 activati…
Given the significant public health burden of Cannabis Use Disorder and the scarcity of effective pharmacological interventions, a successful outcome from this trial could be transformative. Tirzepatide, a dual GLP-1 …
This study provides crucial reassurance for both clinicians and patients regarding the dermatologic safety of GLP-1 RAs, a widely prescribed class of drugs for type 2 diabetes. The findings support the continued use o…
This case highlights a crucial, though likely rare, adverse event associated with rapid weight loss induced by semaglutide, a widely used GLP-1 receptor agonist. Clinicians prescribing semaglutide should be aware of t…
This study provides crucial evidence suggesting that Tirzepatide offers superior weight loss efficacy compared to oral semaglutide, which can significantly inform clinical decision-making for managing overweight and o…
This case report carries significant clinical implications, particularly for endocrinologists and primary care providers prescribing tirzepatide to patients with complex endocrine histories. The finding underscores th…
This systematic review provides compelling evidence that THR-β agonists may represent a more effective treatment strategy for noncirrhotic MASH compared to incretin therapies, particularly concerning histological reso…
This review highlights the broad therapeutic potential of GLP-1RAs and dual GIP/GLP-1RAs, suggesting they could become cornerstone treatments for a multitude of conditions beyond their current approvals. The identifie…
Optimizing Survodutide's formulation is critical for its future development as a potential treatment for obesity and NASH. A formulation with improved bioavailability could lead to more effective dosing strategies, po…
If the results demonstrate significant efficacy, survodutide could represent a transformative new therapeutic option for individuals struggling with the dual burden of overweight/obesity and Type 2 Diabetes. As a dual…
Understanding Liraglutide's direct effects on inflammation could significantly broaden its therapeutic implications beyond glycemic control and weight management. If Liraglutide can effectively reduce adipose tissue i…
If liraglutide were found to be effective and safe as an add-on therapy for Type 1 Diabetes, it could represent a significant advancement in managing this complex condition. Such a finding could potentially lead to im…
Identifying predictive biomarkers for Liraglutide response could revolutionize obesity treatment by enabling personalized medicine. If successful, this research could allow clinicians to prescribe Saxenda® more effect…
Understanding how age affects Liraglutide's pharmacokinetics is crucial for optimizing treatment strategies, especially given the increasing prevalence of type 2 diabetes and obesity in the elderly population. If sign…